EU/3/07/442
About
On 20 March 2007, orphan designation (EU/3/07/442) was granted by the European Commission to Eli Lilly Nederland B.V., The Netherlands, for enzastaurin hydrochloride for the diffuse large B cell lymphoma.
The sponsorship was transferred to Isabelle Ramirez, Germany, in February 2016.
The sponsorship was transferred to Dlrc Pharma Services Limited, Ireland, in October 2020.
Key facts
Active substance |
Enzastaurin hydrochloride
|
Disease / condition |
Treatment of diffuse large B-cell lymphoma
|
Date of first decision |
20/03/2007
|
Outcome |
Positive
|
EU designation number |
EU/3/07/442
|
Sponsor's contact details
Dlrc Pharma Services Limited
Chesterfield House
Clonmannon
Ashford A67 WR29
Co. Wicklow
Ireland
E-mail: regulatory.submissions@dlrc.eu
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.